Nateglinide, a novel D-phenylalanine derivative, stimulates insulin release via closure of KATP channels in pancreatic //-cell, a primary mechanism of action it shares with sulfonylureas (SUs) and repaglinide. This study investigated (1) the influence of ambient glucose levels on the insulinotropic effects of nateglinide, glyburide and repaglinide, and (2) the influence of the antidiabetic agents on glucose-stimulated insulin secretion (GSIS) in vitro from isolated rat islets. The EC50 of nateglinide to stimulate insulin secretion was 14 M in the presence of 3mM glucose and was reduced by 6- 
INTRODUCTION
The homeostatic maintenance of blood glucose concentration is an integrated process predominantly regulated by the anti-hyperglycemic hormone insulin. When blood glucose rises, uptake of glucose into the/-cells leads to an elevation of ATP/ADP ratio and a sequence of ionic events. The resultant increase in intracellular Ca 2 +triggers exocytosis and insulin release. [1] The generation of insulin occurs through a precursor, proinsulin, whose biosynthesis is stimulated by nutrient secretagogue like glucose. [2] Aside from nutrient secretagogues, there are a number of non-nutrient *Address for correspondence: Metabolic KATP channels. [3] [4] [5] Agents that share the primary mechanism of action with SUs include repaglinide (REP), a non-SUs benzoic acid derivative, [6] [7] [8] and nateglinide (NAT), a novel oral hypoglycemic agent recently marketed. [9, 1] The structures of these hypoglycemic agents are shown in Figure 1 .
In treating type 2 diabetes, SUs and REP can cause long-lasting hypoglycemia under both normoglycemic and hyperglycemic conditions in animal models. [11, 2] NAT, on the other hand, demonstrates an enhanced activity under hyperglycemic conditions due to glucosesensitive action. [9, 3, 141 In line with the in vivo data, our earlier study characterizing the KATP channel-blocking effect by hypoglycemic drugs showed that NAT but not GLY and REP had an increased potency at elevated glucose concentration. [ Assay (SPA) The incubation media were diluted by factors ranging from lx to 20x depending on the concentrations of glucose/drugs/inhibitors. The diluted media were assayed for insulin content with SPA. [17] The assay employed commercially available products including a guinea pig anti-rat insulin specific antibody ( _ _ _ 13.5 U/islet at G3, GS, and at G16 (n =96), demonstrating a glucose-dependence of insulin secretion. The ability of NAT, GLY and REP to stimulate insulin secretion was evaluated when the glucose concentration was maintained at 3 (G3), 8 Figure 5A illustrates the data of glucoseinsulin response pooled from six independent experiments (n =4 in each experiment). The [21] It is therefore conceivable that nutrient-free salines are inappropriate for in vitro insulin study. The present study assessed the influence of glucose on in vitro insulin secretion stimulated by hypoglycemic drugs. Our data showed that the augmentation by NAT of insulin release was glucose-sensitive, as evidenced by a respective 6-and 16-fold increase in potency with an elevation of glucose from 3mM to 8 and 16mM. These changes, albeit not drastic, indicated an ability of NAT to "self-correct" for the maintenance of glucose homeostasis. These data are in qualitative agreement with findings from studies utilizing the buffer-perfused pancreas [22] as well as from in vivo studies in rat or dog. [11, 12] The glucose sensitization of the NAT's insulinotropic action in vitro and in vivo and the glucose desensitization of GLY's action are also consistent with the observations that NAT allows whereas SUs prevent nutrient-stimulated protein biosynthesis in f3 cells. [23, 24] The glucose-sensitive insulinotropic effect of NAT predicts that it would be a more effective drug in hyperglycemic patients than in normal individuals, depending, of course on the "health" of the pancreas or the residual /3-cell mass. In addition, the reduced insulinogenic potency of NAT at low glucose level may be translated to an increased safety margin due to reduced propensity of serious hypoglycemia. Conversely, GLY showed a greater potency at low glucose concentrations, which may contribute to relatively high risk of hypoglycemia known to be associated with GLY therapy. [25] [26] [27] The insulinotropic effect of REP was more potent by 5- [28] . On the other hand, the insulinotropic action of NAT is likely to be mediated by KATP channel-independent as well as KATP channel-dependent pathways, while that of REP appears to be solely due to its closing of KATP channels in /-cells. [7, 29] [33] have been proposed to be responsible for the common and differential insulin-stimulating processes by these drugs. Alternatively, the sensitizing or desensitizing efficacy of hypoglycemic agents on GSIS may be linked to differences in their capacity to be inserted into the phospholipid domain of the plasma membrane. SUs, GLY and GLI, have been known to be internalized into -cells to exert their action [21, 341 while NAT appears to act extracellularly. [35] 
